Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does Not Meet First or Second Primary Endpoint

By: via Benzinga
Agenus (NASDAQ: AGEN) today announced that GlaxoSmithKline's (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.